Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|January 8, 2025

White Paper: The PAT Pathway to Scalable and Sustainable Precision Fermentation

Author(s)Hamilton

Precision fermentation, a sustainable method for producing alternative food ingredients, faces significant technical challenges. This white paper explores the critical role of Process Analytical Technology (PAT) in overcoming these hurdles and ensuring product quality through a Quality-by-Design (QbD) approach. Through a comprehensive review of literature and case studies, key technical challenges are identified to demonstrate how PAT can enhance scalability and sustainability. This paper also highlights the transformative potential of PAT in advancing precision fermentation as a reliable solution for addressing nutritional deficiencies and fostering a circular economy.


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.